JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB201060

Anti-beta Amyloid 1-42 抗体 [mOC64]

Anti-beta Amyloid 1-42 antibody [mOC64]

5

(8 Reviews)

|

(140 Publications)

Anti-beta Amyloid 1-42 antibody [mOC64] (ab201060) is a rabbit monoclonal antibody detecting beta Amyloid 1-42 in IHC-P, IHC-Fr, Dot Blot. Suitable for Human, Mouse, Rat.

- Over 80 publications

別名を表示する

A4, AD1, APP, Amyloid-beta precursor protein, ABPP, APPI, Alzheimer disease amyloid A4 protein homolog, Alzheimer disease amyloid protein, Amyloid precursor protein, Amyloid-beta (A4) precursor protein, Amyloid-beta A4 protein, Cerebral vascular amyloid peptide, PreA4, Protease nexin-II, CVAP, PN-II

4 Images
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-beta Amyloid 1-42 antibody [mOC64] (AB201060)
  • IHC-P

Lab

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-beta Amyloid 1-42 antibody [mOC64] (AB201060)

Immunohistochemical analysis of formalin fixed paraffin embedded human alzheimer brain labelling beta Amyloid with ab201060 at a concentration of 0.1μg/ml. The immunostaining was performed on a Ventana DISCOVERY ULTRA (Roche Tissue Diagnostics) instrument with a OptiView DAB IHC Detection Kit. Heat mediated antigen retrieval was performed with DISCOVERY cell conditioning solution (CC1) 100°C, pH8.5 for 32mins.

ab201060 Anti-beta Amyloid 1-42 antibody [mOC64] was incubated for 16mins at 37°C. Sections were counterstained with Hematoxylin II. Image inset shows absence of staining in secondary antibody only control.

Customers are encouraged to optimise antigen retrieval conditions, antibody concentration, incubation times and temperature for best results in their own IHC assay workflow (automated and manual).

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-beta Amyloid 1-42 antibody [mOC64] (AB201060)
  • IHC-P

Lab

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-beta Amyloid 1-42 antibody [mOC64] (AB201060)

Composite multiplex immunofluorescence staining of APP, PSD95 and Tau staining in a section of formalin-fixed paraffin-embedded human Alzheimer’s brain*.

Performed on a Leica BOND. The section was pre-treated using heat mediated antigen retrieval with EDTA (Ph9.0) using retrieval settings of 100°C for 40 minutes. The section was then incubated at room temperature for 1 hour with ab201060 at 1µg/ml dilution (shown in green), ab317793 at 1µg/ml (shown in magenta), and ab317841 at 1µg/ml (shown in yellow). Then incubated for 1 hour with ab150118 Goat Anti-Mouse IgG H&L (Alexa Fluor® 555) preadsorbed 1/1000, ab150081 Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) preadsorbed 1/1000, and ab150135 Donkey Anti-Goat IgG H&L (Alexa Fluor® 647) preadsorbed 1/1000. Nuclear DNA was labelled with DAPI (shown in blue). The section was then mounted using Dako Fluorescence Mounting Medium ®.

Image was taken with a confocal microscope (Leica-Microsystems, TCS SP8).

For other IHC staining systems (automated and non-automated), customers should optimize variable parameters such as antigen retrieval conditions, antibody concentrations and incubation times.

*Tissue obtained from the Human Research Tissue Bank, supported by the NIHR Cambridge Biomedical Research Centre.

Dot Blot - Anti-beta Amyloid 1-42 antibody [mOC64] (AB201060)
  • Dot

Supplier Data

Dot Blot - Anti-beta Amyloid 1-42 antibody [mOC64] (AB201060)

Dot blot analysis of human beta Amyloid 1-42 labeled with ab201060 at 1/7000 dilution.
Lane 1 : beta Amyloid (Aβ) 1-40.
Lane 2 : beta Amyloid (Aβ) 1-42.
Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (ab97051) at 1/5000 dilution was used as secondary antibody.
Blocking and diluting buffer : 5% NFDM/TBST.
Exposure time : 30 seconds.

Antibody reactivity was assessed using a dot blot, which is a non-quantitative method that maintains the native conformation of beta Amyloid. Beta Amyloid 1-40 and 1-42 peptides underwent the following aggregation conditions before being spotted onto a nitrocellulose membrane and detected using ab201060 :
Monomers : 0.3 mg of beta Amyloid peptide was dissolved in 30 μl 100 mM NaOH and incubated at room temperature for 10 minutes. It was then diluted with 970 μl of 1% SDS and boiled for five minutes.
Oligomers : 0.3 mg of beta Amyloid peptide was dissolved in 30 μl 100 mM NaOH and incubated at room temperature for 10 minutes. It was then diluted with 970 μl of 10 mM phosphate buffer pH 7.4 containing 0.02% sodium azide and incubated at room temperature for four days.
Fibrils : 0.3 mg of beta Amyloid peptide was dissolved in 1 ml 50% hexafluoroisopropanol (HFIP) with 0.02% sodium azide. It was then stirred constantly for nine days; the first seven with a cap on and the final two with the cap removed to allow evaporation of the HFIP. Fibrils were then sedimented at 20,000 rpm in a microcentrifuge for 20 minutes and resuspended in 1 ml of PBS + 0.02% sodium azide.

Dot Blot - Anti-beta Amyloid 1-42 antibody [mOC64] (AB201060)
  • Dot

Supplier Data

Dot Blot - Anti-beta Amyloid 1-42 antibody [mOC64] (AB201060)

Negative control (secondary ab only) :

Lane 1 : Human beta Amyloid (Aβ) 1-40.
Lane 2 : Human beta Amyloid (Aβ) 1-42.
Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (ab97051) at 1/5000 dilution was used as secondary antibody.
Blocking and diluting buffer : 5% NFDM/TBST.
Exposure time : 30 seconds.

関連する標識済み抗体及び組成の異なる製品 (7)

  • 519 Alexa Fluor® 488

    Alexa Fluor® 488 Anti-beta Amyloid 1-42 antibody [mOC64]

  • Carrier free

    Anti-beta Amyloid 1-42 antibody [mOC64] - BSA and Azide free

  • 665 Alexa Fluor® 647

    Alexa Fluor® 647 Anti-beta Amyloid 1-42 antibody [mOC64]

  • 603 Alexa Fluor® 568

    Alexa Fluor® 568 Anti-beta Amyloid 1-42 antibody [mOC64]

  • 565 Alexa Fluor® 555

    Alexa Fluor® 555 Anti-beta Amyloid 1-42 antibody [mOC64]

  • Carrier free

    Anti-beta Amyloid 1-42 antibody [mOC64] - Low endotoxin, Azide free

  • 665 Alexa Fluor® 647

    Alexa Fluor® 647 Anti-beta Amyloid 1-42 antibody [mOC64]

Key facts

宿主種

Rabbit

クローン性

Monoclonal

クローン番号

mOC64

アイソタイプ

IgG

キャリアフリー

No

交差種

Mouse, Rat, Human

アプリケーション

IHC-FrFl, Dot, IHC-P

applications

特異性

This antibody recognizes monomeric, oligomeric and fibrillar forms of beta Amyloid 1-42 peptide and reacts weakly with beta Amyloid 1-40.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"}, "Dot" : {"fullname" : "Dot Blot", "shortname":"Dot"}, "IHCFrFl" : {"fullname" : "Immunohistochemistry - Free Floating", "shortname":"IHC-FrFl"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "1/1000", "IHCP-species-notes": "<p></p> Perform heat-mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.", "Dot-species-checked": "testedAndGuaranteed", "Dot-species-dilution-info": "1/7000", "Dot-species-notes": "<p></p>", "IHCFrFl-species-checked": "guaranteed", "IHCFrFl-species-dilution-info": "", "IHCFrFl-species-notes": "" }, "Mouse": { "IHCP-species-checked": "guaranteed", "IHCP-species-dilution-info": "1/1000", "IHCP-species-notes": "<p></p> Perform heat-mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.", "Dot-species-checked": "testedAndGuaranteed", "Dot-species-dilution-info": "1/7000", "Dot-species-notes": "<p></p>", "IHCFrFl-species-checked": "testedAndGuaranteed", "IHCFrFl-species-dilution-info": "", "IHCFrFl-species-notes": "<p></p>" }, "Rat": { "IHCP-species-checked": "guaranteed", "IHCP-species-dilution-info": "1/1000", "IHCP-species-notes": "<p></p> Perform heat-mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.", "Dot-species-checked": "guaranteed", "Dot-species-dilution-info": "1/7000", "Dot-species-notes": "<p></p>", "IHCFrFl-species-checked": "guaranteed", "IHCFrFl-species-dilution-info": "", "IHCFrFl-species-notes": "<p></p>" } } }

製品の詳細

Anti-beta Amyloid 1-42 antibody [mOC64] (ab201060) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in Dot blot, IHC-FrFl, IHC-P in human, mouse, rat samples.

Anti-beta Amyloid 1-42 antibody [mOC64] (ab201060) has been cited over 82 times in peer reviewed journals and is trusted by the scientific community.

Abcam's high quality manufacturing and validation processes ensure Anti-beta Amyloid 1-42 antibody [mOC64] (ab201060) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility.

Anti-beta Amyloid 1-42 antibody [mOC64] (ab201060) has 8 independent reviews from customers.

Anti-beta Amyloid 1-42 antibody [mOC64] (ab201060) specifically detects beta Amyloid 1-42 (UniProt ID: P05067; Molecular weight: 85kDa) and is sold in a convenient trial size to enable initial testing (20 µL) and larger sizes for subsequent scaling up experiments (100 µL and 1 mL).

Conjugation-ready, carrier free format available for antibody clone mOC64 - ab271968.

Antibody clone mOC64 is also available pre-conjugated to a variety of labels for your convenience - Alexa Fluor® 647, Alexa Fluor® 488, Alexa Fluor® 647, Alexa Fluor® 555, Alexa Fluor® 568 (ab224025, ab224026, ab300742, ab302544, ab302803).

This antibody was developed as part of a collaboration between Abcam and Professor Charles Glabe, UC Irvine.

mOC64 immunoreactivity maps to residues 3-6 (EFRH) of Aß. It does not recognize pyproglytaminylated Aß at position 3 (Aß3(pE)–42) (Nussbaum et al. 2012, PMID: 22660329 and Hatami et al. 2014, PMID: 25281743).

For further information on the immunogen, please refer to Hatami et al. 2014, 25281743 and Kayed et al. 2007, PMID: 17897471.

Browse our curated portfolio of extensively validated recombinant antibodies and assays sensitive to Tau, Beta-amyloid, and other Alzheimer’s targets of interest, with everything you need in one place.

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

出荷温度及び保存条件

製品の状態
Liquid
精製方法
Affinity purification Protein A
バッファー組成
pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
出荷温度
Blue Ice
短期保存期間
1-2 weeks
短期保存温度
+4°C
長期保存温度
-20°C
分注に関する情報
Upon delivery aliquot
保管に関する情報
Avoid freeze / thaw cycle

補足情報

This supplementary information is collated from multiple sources and compiled automatically.

Beta Amyloid 1-42 often referred to as Abeta 42 or amyloid beta 1-42 is a peptide derived from the amyloid precursor protein (APP). This peptide consists of 42 amino acids and has a molecular weight of approximately 4.5 kDa. It is predominantly found in the brain especially within regions associated with memory and cognitive function. Beta amyloid 1-42 is a product of enzymatic cleavage by beta and gamma secretases from the larger APP molecule. Due to its aggregation-prone nature beta amyloid 1-42 is a focus in neuroscience research particularly concerning the formation of amyloid plaques.
Biological function summary

Amyloid beta 1-42 plays a central role in synaptic activity and neuronal health. While not inherently pathogenic its tendency to aggregate forms oligomers and fibrils which become toxic to neurons. This peptide contributes to synaptic dysfunction and neuronal cell death and is a major component of extracellular amyloid plaques found in brain tissue. Within the cellular environment amyloid beta 1-42 can interact with receptors membrane lipids and intracellular signaling mechanisms thereby affecting neuronal cell function.

Pathways

Amyloid beta 1-42 is important in the amyloidogenic pathway which is one of the critical components in APP processing. The pathway includes proteolytic enzymes like beta secretase (BACE1) and gamma secretase where misregulation may lead to excessive production or deposition of amyloid beta peptides. Another related pathway is the tau protein phosphorylation pathway which indirectly interacts with amyloid beta 1-42 due to shared signaling intermediates impacting tau stabilization and microtubule assembly in neurons.

Amyloid beta 1-42 plays a pivotal role in Alzheimer's disease a prevalent neurodegenerative disorder. The excessive accumulation of beta amyloid in the form of plaques is a hallmark of the disease contributing to cognitive decline. Also it has links to cerebral amyloid angiopathy where it deposits in the walls of blood vessels of the central nervous system. Both conditions may involve interactions with tau protein another pathological feature of Alzheimer's disease which undergoes hyperphosphorylation leading to neurofibrillary tangles formation.

製品プロトコール

For this product, it's our understanding that no specific protocols are required. You can visit:

ターゲットの情報

Functions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axonogenesis. Interaction between APP molecules on neighboring cells promotes synaptogenesis (PubMed : 25122912). Involved in cell mobility and transcription regulation through protein-protein interactions. Can promote transcription activation through binding to APBB1-KAT5 and inhibits Notch signaling through interaction with Numb. Couples to apoptosis-inducing pathways such as those mediated by G(o) and JIP. Inhibits G(o) alpha ATPase activity (By similarity). Acts as a kinesin I membrane receptor, mediating the axonal transport of beta-secretase and presenilin 1 (By similarity). By acting as a kinesin I membrane receptor, plays a role in axonal anterograde transport of cargo towards synapses in axons (PubMed : 17062754, PubMed : 23011729). Involved in copper homeostasis/oxidative stress through copper ion reduction. In vitro, copper-metallated APP induces neuronal death directly or is potentiated through Cu(2+)-mediated low-density lipoprotein oxidation. Can regulate neurite outgrowth through binding to components of the extracellular matrix such as heparin and collagen I and IV. The splice isoforms that contain the BPTI domain possess protease inhibitor activity. Induces a AGER-dependent pathway that involves activation of p38 MAPK, resulting in internalization of amyloid-beta peptide and leading to mitochondrial dysfunction in cultured cortical neurons. Provides Cu(2+) ions for GPC1 which are required for release of nitric oxide (NO) and subsequent degradation of the heparan sulfate chains on GPC1.. Amyloid-beta peptides are lipophilic metal chelators with metal-reducing activity. Bind transient metals such as copper, zinc and iron. In vitro, can reduce Cu(2+) and Fe(3+) to Cu(+) and Fe(2+), respectively. Amyloid-beta peptides bind to lipoproteins and apolipoproteins E and J in the CSF and to HDL particles in plasma, inhibiting metal-catalyzed oxidation of lipoproteins. Promotes both tau aggregation and TPK II-mediated phosphorylation. Interaction with overexpressed HADH2 leads to oxidative stress and neurotoxicity. Also binds GPC1 in lipid rafts.. Amyloid-beta protein 42. More effective reductant than amyloid-beta protein 40. May activate mononuclear phagocytes in the brain and elicit inflammatory responses.. Appicans elicit adhesion of neural cells to the extracellular matrix and may regulate neurite outgrowth in the brain.. The gamma-CTF peptides as well as the caspase-cleaved peptides, including C31, are potent enhancers of neuronal apoptosis.
See full target information APP

文献 (140)

Recent publications for all applications. Explore the full list and refine your search

European journal of nuclear medicine and molecular imaging : PubMed40956407

2025

Early astrocyte-targeted intervention guided by F-SMBT-1 imaging attenuates disease progression in 3xTg-AD mice.

Applications

Unspecified application

Species

Unspecified reactive species

Shenrui Guo,Feng Wei,Yuge Chang,Shuqi Wu,Zhiyin Lou,Yufei Ma,Qi Huang,Kun He,Chenglai Fu,Xianyi Cao,Sheng Liang,Weiwei Cheng,Yafu Yin

Neuropsychiatric disease and treatment 21:1911-1933 PubMed40926795

2025

Integrated Gut Microbiota, Metabolomics, and Network Pharmacology to Investigate the Anti-Alzheimer's Mechanism of Tripterygium Glycoside.

Applications

Unspecified application

Species

Unspecified reactive species

Yongcang Zhang,Quxi Silang,Yan Wang,Niannian Wang,Luobu Gesang,Liang Tang,Lan Liu

Frontiers in pharmacology 16:1632640 PubMed40771917

2025

The effect of oral administration of NXP032 equivalent to intraperitoneal administration in an Alzheimer's disease model.

Applications

Unspecified application

Species

Unspecified reactive species

Jae Min Lee,You Jung Choi,Da-Eun Sung,Tae Hyeok Sim,So Hee Kim,Seung Geun Yeo,Youn-Jung Kim

eLife 13: PubMed40762561

2025

The novel role of Kallistatin in linking metabolic syndromes and cognitive memory deterioration by inducing amyloid-β plaques accumulation and tau protein hyperphosphorylation.

Applications

Unspecified application

Species

Unspecified reactive species

Weiwei Qi,Yanlan Long,Ziming Li,Zhen Zhao,Jinhui Shi,Wanting Xie,Laijian Wang,Yandan Tan,Ti Zhou,Minting Liang,Ping Jiang,Bin Jiang,Xia Yang,Guoquan Gao

iScience 28:112817 PubMed40599314

2025

Metabolomic and microbial insights: Kai-Xin-San's impact on Alzheimer's disease pathology.

Applications

Unspecified application

Species

Unspecified reactive species

Huifen Ma,Zhiyang Yu,Qiong Qiao,Wenpan Wang,Zhonghua Li,Pan Wang,Junying Song,Xiaowei Zhang,Yunfang Su,Yiran Sun,Zhishen Xie,Zhenqiang Zhang

Aging and disease : PubMed40586384

2025

Stroke Exacerbates Respiratory Disorder and Cognition Impairment in Mice with Cerebral Amyloid Angiopathy.

Applications

Unspecified application

Species

Unspecified reactive species

YuXing Zhang,Ahmad El Hamamy,Zahid Iqbal,Arya Ranjan,Destiny Sumani,Hung Wen Lin,Louise D McCullough,Jun Li

Alzheimer's research & therapy 17:141 PubMed40551167

2025

Photobiomodulation mitigates blood-brain barrier disruption in APP/PS1 mouse model of Alzheimer's disease by activating the AMPK pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Chunyan Ma,Yutong Ye,Xinyu Shi,Na Li,Zhiming Mu,Tao Tan,Huijuan Yin,Jianwu Dai,Yi Liu,Hongli Chen

Materials today. Bio 32:101841 PubMed40469696

2025

Multifunctional natural chlorogenic acid based nanocarrier for Alzheimer's disease treatment.

Applications

Unspecified application

Species

Unspecified reactive species

Chenchen Wang,Xiaolei Song,Xiaowan Zhang,Peng Li,Wei Wei,Shihao Sun,Yong Chen

Frontiers in aging neuroscience 17:1579411 PubMed40443793

2025

Mirodenafil improves cognitive function by reducing microglial activation and blood-brain barrier permeability in ApoE4 KI mice.

Applications

Unspecified application

Species

Unspecified reactive species

Yejin Park,Subin Moon,Harry Jung,Songyi Park,Ju Won Kim,Dan-Gyeong Song,Yong-Ho In,Sang Won Han,Jong-Hee Sohn,Chan Hee Lee

Neurophotonics 12:S14610 PubMed40405889

2025

Characterizing vascular function in mouse models of Alzheimer's disease, atherosclerosis, and mixed Alzheimer's and atherosclerosis.

Applications

Unspecified application

Species

Unspecified reactive species

Beth Eyre,Kira Shaw,Dave Drew,Alexandra Rayson,Osman Shabir,Llywelyn Lee,Sheila Francis,Jason Berwick,Clare Howarth
View all publications

Abcam product promise

当社は、高品質な試薬を通じてお客様の研究を力強くサポートすることをお約束いたします。ご使用いただく各段階で、常にお客様をサポートできる体制を整えております。万が一、製品が期待通りに機能しない場合は、「Abcam Product Promise」による当社保証制度に基づき、安心してご利用いただけます。
保証に関する詳細については利用規約をご確認ください。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com